Once-a-day fractionated total-body irradiation: A regimen tailored to local logistics in allogeneic stem cell transplantation for acute lymphoblastic leukemia.
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
14
09
2018
accepted:
20
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
ppublish
Résumé
The objective of the study was to estimate the cumulative incidence (CI) of relapse, relapse-free survival (RFS) and overall survival (OS) in ALL patients after a once-a-day fractionated TBI (F-TBI) regimen with 9.9 Gy. The secondary objectives were evaluation of short and long-term toxicity and non-relapse mortality (NRM). Total body irradiation (TBI), as a part of the conditioning regimen before allogeneic stem cell transplantation (ASCT) for acute lymphoblastic leukemia (ALL), allows disease control by eradicating residual blast cells in the transplant recipient. Retrospective study conducted in patients with ALL who received between March 2003 and December 2013 a conditioning regimen with F-TBI and chemotherapy. Irradiation was delivered with 3.3 Gy once-a-day for three consecutive days. Eighty-seven patients were included. The median age was 19 years (range: 5-49 years). The 3-year CI of relapse was 30%. The estimated 3-year RFS and OS were 54% and 58%, respectively. Cumulative incidence of acute graft-versus-host disease (aGVHD) grade II-IV and chronic GVHD (cGVHD) was 31% and 40%, respectively. Interstitial pneumonitis was observed in 2 patients. The 3-year CI of NRM was 16%. In multivariate analysis, cGVHD was associated with a lower CI of relapse (RR = 0.26, 95% CI: 0.07-0.95, Once-a-day F-TBI regimen is effective, safe and practical in patients who underwent ASCT for ALL.
Sections du résumé
AIM
OBJECTIVE
The objective of the study was to estimate the cumulative incidence (CI) of relapse, relapse-free survival (RFS) and overall survival (OS) in ALL patients after a once-a-day fractionated TBI (F-TBI) regimen with 9.9 Gy. The secondary objectives were evaluation of short and long-term toxicity and non-relapse mortality (NRM).
BACKGROUND
BACKGROUND
Total body irradiation (TBI), as a part of the conditioning regimen before allogeneic stem cell transplantation (ASCT) for acute lymphoblastic leukemia (ALL), allows disease control by eradicating residual blast cells in the transplant recipient.
MATERIALS AND METHODS
METHODS
Retrospective study conducted in patients with ALL who received between March 2003 and December 2013 a conditioning regimen with F-TBI and chemotherapy. Irradiation was delivered with 3.3 Gy once-a-day for three consecutive days.
RESULTS
RESULTS
Eighty-seven patients were included. The median age was 19 years (range: 5-49 years). The 3-year CI of relapse was 30%. The estimated 3-year RFS and OS were 54% and 58%, respectively. Cumulative incidence of acute graft-versus-host disease (aGVHD) grade II-IV and chronic GVHD (cGVHD) was 31% and 40%, respectively. Interstitial pneumonitis was observed in 2 patients. The 3-year CI of NRM was 16%. In multivariate analysis, cGVHD was associated with a lower CI of relapse (RR = 0.26, 95% CI: 0.07-0.95,
CONCLUSIONS
CONCLUSIONS
Once-a-day F-TBI regimen is effective, safe and practical in patients who underwent ASCT for ALL.
Identifiants
pubmed: 32372884
doi: 10.1016/j.rpor.2020.03.023
pii: S1507-1367(20)30052-3
pmc: PMC7195497
doi:
Types de publication
Journal Article
Langues
eng
Pagination
436-441Informations de copyright
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Références
Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53
pubmed: 16545728
Biol Blood Marrow Transplant. 2002;8(3):139-44
pubmed: 11939603
Bone Marrow Transplant. 1993 Dec;12(6):583-9
pubmed: 8136742
Leuk Lymphoma. 2013 Nov;54(11):2474-9
pubmed: 23442062
Int J Radiat Oncol Biol Phys. 1982 May;8(5):817-21
pubmed: 7050046
Haematologica. 2000 Oct;85(10):1060-7
pubmed: 11025598
Br J Haematol. 2000 Jan;108(1):99-104
pubmed: 10651732
Cancer Radiother. 2009 Sep;13(5):428-33
pubmed: 19615929
Radiol Med. 1989 Oct;78(4):367-72
pubmed: 2687967
Br J Haematol. 1983 Nov;55(3):547-54
pubmed: 6357268
Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1071-7
pubmed: 11240249
Exp Hematol. 2003 Oct;31(10):981-6
pubmed: 14550815
Anticancer Res. 2016 Sep;36(9):4859-64
pubmed: 27630341
Tohoku J Exp Med. 2004 Apr;202(4):255-63
pubmed: 15109123
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):483-8
pubmed: 11872296
Radiat Med. 2007 Oct;25(8):407-10
pubmed: 17952545
Strahlenther Onkol. 1998 Feb;174(2):92-104
pubmed: 9487372
Springerplus. 2013 Aug 30;2:424
pubmed: 24040584
N Engl J Med. 1997 Mar 27;336(13):897-904
pubmed: 9070469
Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):497-503
pubmed: 10078628
Bone Marrow Transplant. 2007 Aug;40(4):381-7
pubmed: 17563735